Next-generation sequencing (NGS) technologies have progressive advantages in terms of cost-effectiveness, unprecedented sequencing speed, high resolution and accuracy in genomic analyses, thus are playing an increasing important role in fields of oncology and immunology. Through our cutting-edge SuPrecision™ platform, Creative Biolabs offers high-quality NGS-based services, such as whole genome sequencing (WGS), whole exome sequencing (WES), target sequencing, whole transcriptome sequencing (WTS) and immune repertoire sequencing. The applications of these advanced technologies have been summarized as follows:
NGS in genomic medicine has been driven by low cost, high throughput sequencing and rapid advances in our understanding of the genetic bases of human diseases. The NGS-based method has dominated sequencing space in genomic research, and quickly entered clinical practice. For the reason that unique features of NGS perfectly meet the clinical reality, the NGS technology is becoming a driving force to realize the dream of precision medicine. Moreover, lots of new computational and database-driven tools are emerging to aid in the interpretation of cancer genomic data as its use becomes more and more common in clinical evidence-based cancer medicine.
Applications of Cancer WGS Include but Are Not Limited to:
- Detect all types of somatic/germline including common and rare variants that might otherwise be missed
- Detect all types of nucleotide substitutions, insertions and deletions, copy number variations (CNVs), chromosomal rearrangements, as well as analysis of the non-coding regions
- Unknown genes can be identified as contributing to a disease state
- Obtain high quality de novo assemblies of large and complex genomes
- The change of genetic predisposition caused by lifestyle or environmental factor can be identified
- Genome information can provide valuable information to create personalized plans to treat cancers
Applications of Cancer WES Include but Are Not Limited to:
- Structural variants (SVs) and CNVs detection
- Tumor mutational burden (TMB) analysis
- Minimal residual disease (MRD) monitoring
- Biomarkers discovery
- Identify tumor-specific neoantigen
- Discover rare or common variants associated with a disorder or phenotype
- Determine the sequence of the regulatory regions, such as promoters and non–protein-coding regions, defining the functional parts of the genome
Applications of Cancer Targeted Sequencing Include but Are Not Limited to:
- Selection of genes of interest for a specific cancer
- Targeting known variant for cancer-related genes
- As an important tool for cancer diagnosis and prognosis
Applications of Cancer WTS Include but Are Not Limited to:
- Obtain information regarding mutations/single-nucleotide polymorphisms (SNPs), splice variants, levels of gene expression, gene fusions, genomic rearrangements, allele-specific expression, posttranscriptional modifications, microRNAs, circular RNA (circRNA), and long noncoding RNAs (lncRNAs). Gene expression, either alone or in combination with mutational data, can also be used to investigate spatial and temporal tumor heterogeneity.
- Link the genetic causes of cancer with their phenotypic consequences. The genotypes that can be interrogated include SVs, CNVs, somatic mutations, germline variants and the presence of viruses. Transcriptome profiling for genetic causes and functional phenotypic readouts is shown in the right picture (Cieślik & Chinnaiyan 2018).
Applications of Cancer Immune Repertoire Sequencing Include but Are Not Limited to:
- Germline genes and alleles identification
- B-cell clones identification
- SHM patterns analysis
- T-cell infiltration analysis
- Invariant T-cell identification
- Antigen-specific T-cells identification
- Minimal residual disease quantification
- Regulatory T-cells identification
Enriched experience, profound expertise and state-of-the-art SuPrecision™ platform, all of these can ensure that Creative Biolabs offers high-quality NGS-based services and corresponding bioinformatics analysis services for all our global customers. If you are interested in any of our high-throughput sequencing services, please feel free to contact us for more details.
- Cieślik, M.; & Chinnaiyan. A.M. Cancer transcriptome profiling at the juncture of clinical translation. Nat Rev Genet. 2018, 19(2):93-109.